Dupixent

Active substance

Dupilumab

Holder

Sanofi Belgium

Status

Closed

Indication

Treatment of severe atopic dermatitis in adult patients, uncontrolled with immunosuppressive systemic therapy during the last year.

Public documents

Approbation

Information for the patient

Informed consent

Last update

09/05/2019